Nuvation Bio Inc. (NYSE:NUVB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Nuvation Bio Inc. (NYSE:NUVB) have been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $11.6250.

NUVB has been the subject of a number of research analyst reports. UBS Group cut their price objective on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, March 3rd. HC Wainwright lowered their target price on shares of Nuvation Bio from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. Royal Bank Of Canada raised their target price on shares of Nuvation Bio from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Tuesday, March 3rd. Finally, Citizens Jmp set a $10.00 price target on shares of Nuvation Bio in a report on Thursday, November 20th.

Nuvation Bio Stock Performance

NYSE NUVB opened at $4.44 on Friday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -7.39 and a beta of 1.50. The company has a quick ratio of 6.81, a current ratio of 6.95 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $5.82 and a 200-day moving average price of $5.60. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $9.75.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.The company had revenue of $41.87 million for the quarter, compared to the consensus estimate of $36.82 million. As a group, equities research analysts predict that Nuvation Bio will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Nuvation Bio

Several large investors have recently made changes to their positions in NUVB. Parallel Advisors LLC lifted its position in shares of Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after buying an additional 2,597 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in Nuvation Bio during the 4th quarter valued at approximately $71,000. Swiss Life Asset Management Ltd purchased a new position in Nuvation Bio during the 3rd quarter valued at approximately $39,000. Northwest Quadrant Wealth Management LLC bought a new stake in Nuvation Bio in the 3rd quarter worth approximately $40,000. Finally, HBK Sorce Advisory LLC bought a new stake in Nuvation Bio in the 3rd quarter worth approximately $42,000. 61.67% of the stock is owned by institutional investors.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.